Sold as Delfen, Today. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Nonoxynol-9 (sold as Delfen, Today), first approved Dec 10, 1963, with 0 new uses approved and 0 published complete response letters.
| AI-Augmented Diagnostic Assessment With ENLIGHT Versus Independent Pathologist ReviewCancer · Harvard Medical School (HMS and HSDM) | Not applicable | Enrolling by invitation | Aug 3, 2026 |
| The K-Map Study, Global Prevalence of KCKeratoconus · University Hospital, Geneva | — | Recruiting | Apr 14, 2017 |
| Dec 10, 1963 | DelfenNDA 14349 · New dosage form | Personal Prods | 15 | Discontinued |
| Apr 1, 1983 | TodayNDA 18683 · New dosage form | Mayer Labs Inc | 26 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
